Loading...
01/11 03:35
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals concerns about increased price competition, mixed project quality, and reliance on a few customers. EBITDA margins are decreasing, and there is uncertainty in backlog growth and bookings due to cancellations. Despite share repurchases, the Q&A highlights risks like funding issues and lack of clear guidance. These factors, combined with a decrease in net new business awards, suggest a negative sentiment likely affecting stock price.
Revenue $558.6 million, a year-over-year increase of 9.3%.
Net New Business Awards $500 million, a decrease of 18.8% from the prior year.
Ending Backlog $2.8 billion, a decrease of 2.1% from the prior year.
EBITDA $118.6 million, an increase of 2.6% compared to $115.7 million in Q1 2024.
EBITDA Margin 21.2%, down from 22.6% in the prior year, impacted by employee-related costs and foreign exchange.
Net Income $114.6 million, an increase of 11.7% compared to $102.6 million in the prior year.
Net Income per Diluted Share $3.67, compared to $3.20 in the prior year.
Cash Flow from Operating Activities $125.8 million.
Cash $441.4 million.
Share Repurchases Approximately 1.19 million shares or $389.8 million.
Remaining Share Repurchase Authorization $344.8 million.
Net Days Sales Outstanding Negative 67.8 days.
Revenue Growth: Revenue for the first quarter of 2025 was $558.6 million, which represents a year-over-year increase of 9.3%.
Backlog: Ending backlog as of March 31, 2025, was approximately $2.8 billion, a decrease of 2.1% from the prior year.
Net New Business Awards: Net new business awards entering backlog in the first quarter decreased 18.8% from the prior year to $500 million.
Guidance for 2025 Revenue: Full year 2025 total revenue is now expected in the range of $2.14 billion to $2.24 billion, representing growth of 1.5% to 6.2% over 2024 total revenue of $2.11 billion.
EBITDA Margin: EBITDA margin for the first quarter was 21.2% compared to 22.6% in the prior year period.
Cash Flow from Operations: In the first quarter, we generated $125.8 million in cash flow from operating activities.
Share Repurchase: During the first quarter, we repurchased approximately 1.19 million shares or $389.8 million.
Book-to-Bill Ratio: Net book-to-bill ratio of 0.90, with expectations of improving to above 1.15 in Q3 and Q4.
Customer Concentration: Top five and top ten customers represented roughly 22% and 32% respectively, of first quarter 2025 revenue.
Net Awards and Book-to-Bill Ratio: Net awards were down sequentially and year over year, with a net book-to-bill ratio of 0.90, primarily due to high pipeline cancellations in prior quarters.
Backlog Cancellations: Backlog cancellations were modestly elevated in Q1, with pre-backlog cancellations being worse, impacting future projected backlog net awards.
RFP Flow and Quality: RFP flow was strong in Q1, but the quality was variable and decisions are slowing, which could affect future business.
Economic Climate: Future backlog growth and book-to-bill ratios depend on moderating cancellations and an improved business climate.
EBITDA Margin: EBITDA margin decreased to 21.2% from 22.6% in the prior year, impacted by employee-related costs and foreign exchange due to a weakening US dollar.
Customer Concentration: Top five and top ten customers represented roughly 22% and 32% of revenue respectively, indicating potential risk from customer concentration.
Net Book-to-Bill Ratio: The net book-to-bill ratio was 0.90, reflecting high pipeline cancellations in prior quarters.
Backlog Growth: The company anticipates improved backlog growth with book-to-bill ratios above 1.15 in Q3 and Q4, contingent on moderating cancellations and an improved business climate.
2025 Total Revenue Guidance: Full year 2025 total revenue is expected in the range of $2.14 billion to $2.24 billion, representing growth of 1.5% to 6.2% over 2024.
2025 EBITDA Guidance: 2025 EBITDA is expected in the range of $462 million to $492 million, representing a decline of 3.8% to growth of 2.5% compared to 2024.
2025 Net Income Guidance: Forecasted net income for 2025 is in the range of $378 million to $402 million.
Earnings Per Diluted Share Guidance: Earnings per diluted share is expected to be in the range of $12.26 to $13.04.
Share Repurchase: In the first quarter, we repurchased approximately 1.19 million shares or $389.8 million. At the end of the quarter, we had $344.8 million remaining under our share repurchase authorization program.
The earnings call summary indicates strong revenue guidance with a raised outlook, optimistic backlog conversion, and a strategic shift to faster growing therapeutic areas. Despite slower EBITDA growth, the overall sentiment is positive due to improved funding confidence, a strong pre-backlog position, and expected acceleration in hiring. While some uncertainties remain, particularly around cancellations and competition, the positive aspects outweigh them, suggesting a likely stock price increase over the next two weeks.
The earnings call summary indicates mixed signals: improved backlog growth and low cancellations are positive, but the weak win rate and dependency on low cancellations for future success are concerning. The Q&A reveals management's reluctance to provide specific long-term guidance, adding uncertainty. Despite improved productivity and revenue growth, reliance on pass-through revenue and potential headwinds in 2025 suggest caution. These factors, combined with management's vague responses, lead to a neutral sentiment, anticipating minimal stock price movement.
The earnings call reveals concerns about increased price competition, mixed project quality, and reliance on a few customers. EBITDA margins are decreasing, and there is uncertainty in backlog growth and bookings due to cancellations. Despite share repurchases, the Q&A highlights risks like funding issues and lack of clear guidance. These factors, combined with a decrease in net new business awards, suggest a negative sentiment likely affecting stock price.
The earnings call presents mixed signals with some positive financial metrics but several concerns. Revenue and net income showed growth, but there are significant risks: a low book-to-bill ratio, elevated backlog cancellations, and increased price competition. Guidance reflects modest growth, with potential operational challenges. The Q&A highlights concerns over cancellations, price competition, and client funding issues. Although share repurchases are positive, overall sentiment is negative due to operational uncertainties and external risks. Without market cap data, assume a moderate reaction, leading to a predicted stock price movement in the negative range (-2% to -8%).
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
